|
Report Date : |
17.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
AGP (PVT)
LIMITED |
|
|
|
|
Registered Office : |
B-23, S.I.T.E., |
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
1957 |
|
|
|
|
Com. Reg. No.: |
0000908 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture
& Marketing of Pharmaceutical Products |
|
|
|
|
No. of Employees : |
280 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
|
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
AGP (PVT) LIMITED
|
Registered
Address & Factory |
|
B-23, S.I.T.E., |
|
Tel # |
92 (21) 111-247-247, 32565694 |
|
Fax # |
92 (21) 32570689 |
|
a. |
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1957 |
|
c. |
Registration # |
0000908 |
|
In Hyderabad, Sukkur,
Quetta, Multan, Faisalabad, Lahore, Gujranwala, Rawalpindi & Peshawar |
|
Ernst & Young Ford Rhodes Sidat Hyder (Chartered Accountants) 601-603, Progressive Plaza, Beaumont Road, Karachi, Pakistan |
|
Subject Company was established as a Private Limited Company in 1957 |
|
6. |
Authorized Capital |
Rs. 300,000,000/-
divided into 300,000 shares of Rs. 1000/- each |
|
|
Issued & Paid up Capital |
Rs. 6,580,000/-
divided into 6,580 shares of Rs. 1000/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mrs. Nusrat Munshi Mr. Asif Gohar Mr. Marzook Mahfooz |
Pakistani Pakistani Pakistani |
Flat No. A-50, Galaxy Skyline, Plot No. 28-A, Phase VI, D.H.A.,
Karachi 6-A/II, 10th South Street Extension, Defence Housing
Authority, Karachi 5/A, 11th South Street Extension,
Defence Housing Authority, Karachi |
Business Business Business |
Chief Executive Director Director |
|
Names |
No. of Shares |
|
Mr. Asif Gohar Mr. Marzook Mahfooz Pharmonte Limited, Switzerland |
4,995 5 1,580 |
A. Subsidiary
None
B. Associated
Companies
(1) Sanofi Aventis Pakistan Limited, Pakistan.
(2) The Anglo French Drug Company Pakistan (Pvt)
Limited, Pakistan.
(3) Eli Lilly Gohar (Private) Limited, Pakistan.
(4) Avery Scales (Pvt) Limited, Pakistan.
(5) AGT Systems (Pvt) Limited, Pakistan.
(6) Trade Wind Associates (Pvt) Limited, Pakistan.
(7) Bayer CropScience (Pvt) Limited, Pakistan.
(8) Ali Gohar & Company (Pvt) Limited, Pakistan.
|
ACTI-5, ADAMON, ALGOCIN, ANAFORTAN, ASTELIN, BETADINE, CHYMORAL,
CONTROLOC, CROMETIN A, CROZYL, CYTEAL, DOLOFEN, DOLOFLAM, EKSALB, ENZAR,
GLUCONORM, GROFENAC, HAPRO, LUCAST, MAGNOPYROL, MAGNUS, MAXNA, MELFAX, MERLON,
MIKAN, CONTINUS, NEOGENE, OSLIN, OSSOPAN 800, PANTOLAX, PERMIXON, PHYLLOCONTIN, POSTERISAN FORTE,
PROCLOR, PROLIXAN, RHINOLAST, RIGIX, RIOPAN 800, RUBIFER, SINAXAMOL PLUS,
SINUPRET, SOMATOSAN, SPASLER, SPASLER NEO, TARDYFERON, TEBOKAN FORTE, |
280
|
The capacity and production of the Company’s
plant is indeterminable as it is multi-product and involves varying processes
of manufacture. |
|
Year |
In Pak Rupees |
|
2010 |
700,000,000/- (Estimated) |
|
(1) ALEMBIC LIMITED, INDIA. (2) AUROBINDO PHARMA LIMITED, INDIA. (3) CIPLA LIMITED, INDIA. (4) DEPA PHARMACEUTICAL ACTIVE MATERIAL
INC, TURKEY. (5) JUPITER BIOSCIENCE LIMITED, INDIA. (6) KAIRAV CHEMICALS LIMITED, INDIA. (7) LUPIN CHEMICALS LIMITED, THAILAND. (8) NITSON LABORATORIES, INDIA. (9) POL PHARMA S.A., POLAND. (10) PCAS PHARMA SYNTHESIS, FRANCE. (11) RASULA PHARMA & FINE CHEMICALS,
INDIA. (12) RANBAXY LABORATORIES LIMITED, INDIA. (13) SCHWARZ PHARMA, IRELAND. (14) WOCKHARDT
LIMITED, INDIA. |
|
Mainly exist at major cities of Pakistan |
|
(1) Allied Bank Limited, Pakistan. (2) Habib Bank Limited, Pakistan. (3) KASB Bank Limited, Pakistan. (4) Bank Alfalah Limited, Pakistan. |
·
Karachi Chamber of
Commerce & Industry.(KCCI)
·
Pakistan Pharmaceutical
Manufacturers Association.(PPMA)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 94.80 |
|
UK Pound |
1 |
Rs. 146.70 |
|
Euro |
1 |
Rs. 116.10 |
Subject Company was established in 1957 and is
engaged in manufacture & marketing of Pharmaceutical Products. Market
reputation is satisfactory. Trade relations are reported as fair. Subject can
be considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.92 |
|
|
1 |
Rs.85.47 |
|
Euro |
1 |
Rs.67.15 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.